Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, applied for certification of the manufacturing facility in Sawston, UK with the Medicines and Healthcare Products Regulatory ...
Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month.